- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | FibroBiologics, Inc.: FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate | 172 | PR Newswire | - First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers- On track for interim results reporting in 2H 2026
HOUSTON, July 31... ► Artikel lesen | |
| 24.07. | FibroBiologics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.07. | FibroBiologics, Inc.: FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial | 308 | PR Newswire | Company expects existing supply will suffice to complete clinical trial and lead to cost savings
HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq:... ► Artikel lesen | |
| 26.06. | FibroBiologics prices up to $9M private placement | 1 | Seeking Alpha | ||
| 26.06. | FibroBiologics raises $3M in private placement offering | 3 | Investing.com | ||
| 23.06. | FibroBiologics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 22.06. | FibroBiologics, Inc.: FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing | 180 | GlobeNewswire (Europe) | HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 16.06. | FibroBiologics doses first patients in diabetic foot ulcer trial | 1 | Investing.com | ||
| 16.06. | FibroBiologics, Inc.: FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers | 216 | GlobeNewswire (Europe) | HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 03.06. | FibroBiologics, Inc.: FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers | 270 | GlobeNewswire (Europe) | HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 03.06. | EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial | 1 | Benzinga.com | ||
| 22.05. | FibroBiologics, Inc.: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 11.05. | FibroBiologics, Inc.: FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus | 2 | GlobeNewswire (USA) | ||
| 05.05. | FibroBiologics startet Patientenrekrutierung für Studie zu diabetischem Fußgeschwür | 1 | Investing.com Deutsch | ||
| 04.05. | FibroBiologics reports preclinical burn wound treatment results | 1 | Investing.com | ||
| 04.05. | FibroBiologics, Inc.: FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring | 1 | GlobeNewswire (USA) | ||
| 04.05. | FibroBiologics releases first batch of diabetic ulcer drug | 4 | Investing.com | ||
| 04.05. | FibroBiologics gibt erste Charge von Medikament gegen diabetische Fußgeschwüre frei | 2 | Investing.com Deutsch | ||
| 04.05. | FibroBiologics, Inc.: FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial | 1 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
80 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,90 | -0,19 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| MODERNA | 47,775 | +0,55 % | Moderna dämpft die Kosten, kämpft aber weiter mit hohen Verlusten | Moderna hat im zweiten Quartal 2026 einen Umsatz von 145 Millionen US-Dollar erzielt, nach 142 Millionen US-Dollar im Vorjahresquartal. Rückläufige COVID-Impfstoffverkäufe in den USA und Südamerika... ► Artikel lesen | |
| NOVAVAX | 6,410 | +0,94 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| NANOREPRO | 2,030 | +7,12 % | NanoRepro senkt EBITDA-Minus im Einzelabschluss | Die NanoRepro AG hat ihren geprüften HGB-Einzelabschluss für das Geschäftsjahr 2025 vorgelegt. Auf Ebene der Holding erzielte das Marburger Unternehmen Umsatzerlöse von 4,33 Millionen Euro, nach 4,47... ► Artikel lesen | |
| VIVOSIM LABS | 0,344 | -0,12 % | VivoSim Labs, INC. - S-1, General form for registration of securities | ||
| INOVIO PHARMACEUTICALS | 0,599 | +2,31 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| CLINUVEL | 5,504 | -3,20 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| INFLARX | 1,518 | +3,27 % | InflaRx NV: Innovationskraft und klinische Durchbrüche als Treiber der Aktie | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| DEFENCE THERAPEUTICS | 0,249 | +2,47 % | Defence Therapeutics Inc.: Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform | Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,290 | +2,69 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,992 | +2,67 % | BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer | PARIS (dpa-AFX) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.In... ► Artikel lesen | |
| KUROS BIOSCIENCES | 24,500 | -0,41 % | Schweizer Geheimtipp: Kuros erobert den US-Medizintechnikmarkt: Darum geht die Aktie am Mittwoch steil | UBS nimmt die Coverage von Kuros Biosciences mit Kaufempfehlung auf. Das Kursziel von 33 Franken liegt rund 60 Prozent über dem aktuellen Niveau. Grund ist das Wachstumstempo des Bone-Graft-Produkts... ► Artikel lesen | |
| ABIVAX | 106,80 | -0,28 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,122 | +2,19 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
Das Unternehmen FIBROBIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,84 % bei einem Aktienkurs von 0,706 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FIBROBIOLOGICS INC finden Sie auf Wallstreet Online.